Europe Archives -

Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis

How are the European pharma and biotech sectors addressing strategic communications?

mike.hammerton@pharmaphorum.com Biotech, Communications and Commercialisation, Deep Dive, Deep Dive: Communications and Commercialisation, Europe, Lundquist, Rosanna Campbell-Gray 0 Comment

Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies

How are the European pharma and biotech sectors addressing strategic communications?

https://pharmaphorum.com/sales-marketing/how-are-the-european-pharma-and-biotech-sectors-addressing-strategic-communications/

Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis

BMS’ Catherine Owen: Hybrid communication is here to stay

mike.hammerton@pharmaphorum.com Bristol-Myers Squibb, Canada, Catherine Owen, Communications and Commercialisation, Deep Dive, Deep Dive: Communications and Commercialisation, Dominic Tyer, Europe, Japan 0 Comment

The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of

BMS’ Catherine Owen: Hybrid communication is here to stay

https://pharmaphorum.com/sales-marketing/bms-catherine-owen-hybrid-communication-is-here-to-stay/

News/ News/ Sales and Marketing

Gene therapy specialist bluebird exits “untenable” European market

Phil Taylor bluebird bio, Europe, gene therapy, pricing, rare disease, reimbursement 0 Comment

Europe’s market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene

Gene therapy specialist bluebird exits “untenable” European market

https://pharmaphorum.com/news/gene-therapy-specialist-bluebird-exits-untenable-european-market/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

From representation to empowerment: Putting patients at the centre of medicine reimbursement

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Europe, market access, Vynamic 0 Comment

Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement

From representation to empowerment: Putting patients at the centre of medicine reimbursement

https://pharmaphorum.com/views-analysis-market-access/from-representation-to-empowerment-putting-patients-at-the-centre-of-medicine-reimbursement/

Patients/ Views & Analysis/ Views and analysis

Patients as Partners Europe: Are we doing patient centricity all wrong?

Amanda Barrell Europe, Parkinson's disease, Patients as Partners 0 Comment

To be truly patient centric, do we need to turn the current model on its head and work

Patients as Partners Europe: Are we doing patient centricity all wrong?

https://pharmaphorum.com/views-analysis-patients/pharma-patients-as-partners-europe-patient-centricity/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Why cell therapy manufacture is a team sport

mike.hammerton@pharmaphorum.com cancer, CAR T, cell therapy, EU, Europe, Gilead, Kite, manufacturing 0 Comment

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that

Why cell therapy manufacture is a team sport

https://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/

Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

The calm after the storm: How COVID-19 is making pharma more resilient

Paul Tunnah COVID-19, EU, EU Leaders, Europe, market access, marketing, Sandoz, supply chain 0 Comment

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning

The calm after the storm: How COVID-19 is making pharma more resilient

https://pharmaphorum.com/views-analysis-sales-marketing/the-calm-after-the-storm-how-covid19-is-making-pharma-more-resilient-and-accessible/

Deep Dive/ Digital/ Views & Analysis/ Views and analysis

Germany’s digital health changes will boost digital therapeutics in Europe

mike.hammerton@pharmaphorum.com Deep Dive, digital health, Digital Health Innovation 2020, Europe, Open Health, therapeutics 0 Comment

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating

Germany’s digital health changes will boost digital therapeutics in Europe

https://pharmaphorum.com/views-analysis-digital/germanys-digital-health-changes-will-boost-digital-therapeutics/

Market Access/ News/ News

EMA starts rapid review of Bluebird’s gene therapy for rare disease CALD

Phil Taylor bluebird bio, ema, Europe, gene therapy, genetic diseases, rare disease 0 Comment

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease

EMA starts rapid review of Bluebird’s gene therapy for rare disease CALD

https://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/

Trending

Europe

Login